Please login to the form below

Not currently logged in
Email:
Password:

Silence Therapeutics

This page shows the latest Silence Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Optimum wins Silence Therapeutics account

Optimum wins Silence Therapeutics account

Optimum wins Silence Therapeutics account. The healthcare communications group will advise in financial PR. ... London, UK-based Optimum Strategic Communications has been appointed by RNAi-focused Silence Therapeutics.

Latest news

  • mRNA - message received mRNA - message received

    mRNA replacement opens up entirely new therapeutic areas,” according to Ali Mortazavi, chief executive of UK firm Silence Therapeutics that has just raised almost £40m ($62m) in a fundraising round. “ ... Silence Therapeutics. undisclosed. Antigen

  • Sanofi strikes $700m rare diseases deal Sanofi strikes $700m rare diseases deal

    This pipeline features a series of RNAi therapeutics designed to 'silence' mutated genes in rare genetic diseases in order to stop the disease-causing proteins from being formed.

  • Thomas Christély steps down as Silence Therapeutics CEO after five months

    Thomas Christély has resigned from his role as CEO at Silence Therapeutics after only five months. ... Christély was only appointed CEO in September 2011, having previously held the role of CEO at Silence Therapeutics AG - a subsidiary of Silence

  • Oncology bias in pharma deals

    Silence Therapeutics and miRNA Therapeutics have also signed a collaboration to evaluate delivery of novel microRNA Therapeutics, via Silence's AtuPLEX and DBTC delivery systems. ... not known. Silence Therapeutics/ miRNA Therapeutics. R&D collaboration.

  • Dr Georg Buchner joins Silence Therapeutics

    Dr Georg Buchner joins Silence Therapeutics. He assumes a business development role at the London-based biotech. ... London-based biotech Silence Therapeutics has appointed Dr Georg Buchner VP, business development.

More from news
Approximately 1 fully matching, plus 11 partially matching documents found.

Latest appointments

  • Silence Therapeutics appoints Dr Annalisa Jenkins as non-executive chair Silence Therapeutics appoints Dr Annalisa Jenkins as non-executive chair

    Silence Therapeutics appoints Dr Annalisa Jenkins as non-executive chair. The Dimension Therapeutics CEO succeeds Dr Stephen Parker, who becomes a non-executive director. ... RNA-focused group Silence Therapeutics has appointed Dimension Therapeutics

  • Silence Therapeutics' Ali Mortazavi appointed chairman of ultromics Silence Therapeutics' Ali Mortazavi appointed chairman of ultromics

    Silence Therapeutics' Ali Mortazavi appointed chairman of ultromics. Takes up the non-executive role at the AI-focused medical imaging firm. ... Silence Therapeutics' chief executive officer Ali Mortazavi has been appointed non-executive chairman of

  • Silence Therapeutics adds to leadership team Silence Therapeutics adds to leadership team

    Silence Therapeutics adds to leadership team. Dr Dmitry Samarsky and Dr Andy Richards join. ... London-headquartered RNA therapeutics specialist Silence Therapeutics has appointed Dr Dmitry Samarsky as its new chief scientific officer, to take effect on

  • Stuart Collinson joins Silence Therapeutics Stuart Collinson joins Silence Therapeutics

    Stuart Collinson joins Silence Therapeutics. He replaces Simon Sturge as non-executive director. ... Silence Therapeutics has appointed Dr Stuart Collinson as its new non-executive director and chair of its remuneration committee with immediate effect.

  • Silence appoints chief medical officer Silence appoints chief medical officer

    UK biotech Silence Therapeutics has appointed Dr Michael Khan as its chief medical officer, four months after he joined the company as chief medical adviser. ... Dr Khan said: “ These are very exciting times for Silence Therapeutics, with one oncology

More from appointments
Approximately 6 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera

We live in a time of participation – patients actively involved in their own care recover faster and live longer....

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics